Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
about
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Addition of the p110α inhibito ...... itive-PTEN-loss breast cancer.
@en
type
label
Addition of the p110α inhibito ...... itive-PTEN-loss breast cancer.
@en
prefLabel
Addition of the p110α inhibito ...... itive-PTEN-loss breast cancer.
@en
P2093
P2860
P1433
P1476
Addition of the p110α inhibito ...... itive-PTEN-loss breast cancer.
@en
P2093
P2860
P2888
P304
14831-14839
P356
10.1007/S13277-016-5381-7
P577
2016-09-17T00:00:00Z
P6179
1004854289